The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.
Primary hyperaldosteronism is caused by excessive aldosterone secretion caused by adrenal cortex disease, which leads to increased sodium and potassium discharge, increased fluid volume and inhibition of renin-angiotensin-aldosterone system. It is one of the common causes of secondary hypertension as clinical symptoms with hypertension, hypokalemia, hyperaldosterone and low renin. It accounts for 5% to 13% of people with hypertension. In addition to the impact of hypertension itself on the body, the endocrine hormone disorder and electrolyte imbalance associated with PA may also become independent risk factors for cardiovascular and cerebrovascular events, and the risk of stroke, atrial fibrillation and myocardial infarction is significantly higher than that of essential hypertension, so early detection and reasonable treatment are crucial. PA can be divided into 6 types according to the etiology, of which the most common is idiopathic aldosteronism (IHA) and aldosteronoma, accounting for 60% and 30% respectively, unilateral adrenal hyperplasia followed, the other subtypes are less common. Previous guidelines have recommended surgery and drug intervention as the main measures for the treatment of PA, while unilateral PA is preferred by surgery and laparoscopic adrenalectomy. However, surgical treatment also has many limitations: First, not all patients with surgical indications have the opportunity to undergo adrenal resection. Surgical treatment is not suitable for patients with difficult laparoscopic operation, such as obesity, serious abdominal adhesion due to previous surgical history, and high-risk surgery, such as cardiovascular and cerebrovascular diseases and emphysema. In addition, adrenal resection may lead to adrenal dysfunction, serious infection, retroperitoneal hematoma and many other adverse reactions. The efficacy and safety of superselective adrenal artery embolization as a new alternative therapy for PA intervention have been proved. The aim of this study was to compare the efficacy of adrenectomy and superselective adrenal artery embolization according to international PASO evaluation criteria, and to conduct a prospective, multicenter, randomized controlled study in Xinjiang to explore the potential of SAAE as a treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
570
Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
RECRUITINGComplete biochemical cure of PA
Complete biochemical cure of PA, defined (whilst off medications that might alter serum potassium or the RAS) by both: Normalisation of serum potassium, and Normalisation of ARR, or Elevated ARR and i). Baseline PAC \<190pmol/L, or ii). Normal confirmatory test (as defined in the inclusion criteria)
Time frame: 6 months post intervention
Complete clinical cure of PA
Complete clinical cure of PA, defined as normotension without antihypertensive medication
Time frame: 6 months post intervention
Changes in ambulatory blood pressure and baseline blood pressure
24-hour ambulatory blood pressure and office systolic and diastolic pressure
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of the number of antihypertensive medications
Difference in the change of the number of antihypertensive medications
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Adverse events
Will be directly sought at each study visit through history and physical examination where appropriate Subjects will be encouraged to report between study visits and will have a mechanism to do so Will be classified by system, seriousness, causal relationship and expectedness according to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE)
Time frame: Reported throughout the study period. Approximately 2 years
Readmission rate
Readmission rate, defined as readmission for primary aldosteronism
Time frame: Reported throughout the study period. Approximately 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change of blood electrolytes (K+, Na +)
Difference in the change of blood electrolytes (K+, Na + in mmol/L)
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of plasma aldosterone
Difference in the change of plasma aldosterone (pg/mL)
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of plasma cortisol
Difference in the change of plasma cortisol (nmol/L)
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of plasma renin measured
Difference in the change of plasma renin (pg/ml)
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of liver enzymes
Difference in the change of liver enzymes (ALT, AST in IU/L)
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of kidney function
Difference in the change of serum creatinine in umol/L
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of fasting blood glucose
Difference in the change of fasting blood glucose in mmol/L
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of lipids profiles
Difference in the change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of 24-h urine microalbumin
Difference in the change of 24-h urine microalbumin (mg/L)
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months
Change of 24-h 24-h urine creatinine
Difference in the change of 24-h urine creatinine (umol/L)
Time frame: 1 day, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months